Anhui Fengyuan Pharmaceutical Co., Ltd.

Symbol: 000153.SZ

SHZ

8.55

CNY

Market price today

  • 17.7110

    P/E Ratio

  • 0.1358

    PEG Ratio

  • 2.84B

    MRK Cap

  • 0.01%

    DIV Yield

Anhui Fengyuan Pharmaceutical Co., Ltd. (000153-SZ) Stock Price & Analysis

Shares Outstanding

332.03M

Gross Profit Margin

0.25%

Operating Profit Margin

0.05%

Net Profit Margin

0.04%

Return on Assets

0.03%

Return on Equity

0.09%

Return on Capital Employed

0.09%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Jun Li
Full-time employees:4654
City:Hefei
Address:Baohe industrial park
IPO:2000-09-20
CIK:

Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells biological pharmacy, chemical pharmacy, and traditional Chinese medicines primarily in China. It offers antipyretic-analgesic, cardiovascular, antibiotic, nervous system, anti-tumor, antiulcer, and hormone drugs, as well as nutraceuticals. The company also provides general medicines for vitamin and mineral deficiency; medicines for resisting parasitic diseases and microorganisms; coenzymes; and antiviral and uterine contractive medicines. In addition, it offers sedative-hypnotic drugs; drugs for curing mesenteric stress syndrome; drugs for lowering blood pressure; and drugs for curing benign prostatic hyperplasia. The company also exports its products to Europe, North America, Africa, Southeast Asia, and Central Asia. Anhui Fengyuan Pharmaceutical Co., Ltd. was founded in 1997 and is based in Hefei, China.

General Outlook

In simple terms, Anhui Fengyuan Pharmaceutical Co., Ltd. has 332.026 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.250% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.051%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.038%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.034% return, is a testament to Anhui Fengyuan Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Anhui Fengyuan Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.085%. Furthermore, the proficiency of Anhui Fengyuan Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable 0.087% return on capital employed.

Stock Prices

Anhui Fengyuan Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $8, while its low point bottomed out at $7.85. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Anhui Fengyuan Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 000153.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 94.29% gauges short-term asset coverage for liabilities. The quick ratio (58.45%) assesses immediate liquidity, while the cash ratio (14.91%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio94.29%
Quick Ratio58.45%
Cash Ratio14.91%

Profitability Ratios

000153.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 5.14% underscores its earnings before tax deductions. The effective tax rate stands at 26.67%, revealing its tax efficiency. The net income per EBT, 74.38%, and the EBT per EBIT, 100.67%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 5.11%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin5.14%
Effective Tax Rate26.67%
Net Income per EBT74.38%
EBT per EBIT100.67%
EBIT per Revenue5.11%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.94, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding58
Days of Inventory Outstanding66
Operating Cycle170.22
Days of Payables Outstanding101
Cash Conversion Cycle69
Receivables Turnover3.51
Payables Turnover3.61
Inventory Turnover5.52
Fixed Asset Turnover2.74
Asset Turnover0.89

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.75, and free cash flow per share, 0.29, depict cash generation on a per-share basis. The cash per share value, 0.37, showcases liquidity position. A payout ratio of 0.39 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.06, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.75
Free Cash Flow per Share0.29
Cash per Share0.37
Payout Ratio0.39
Operating Cash Flow Sales Ratio0.06
Free Cash Flow to Operating Cash Flow Ratio0.39
Cash Flow Coverage Ratio0.30
Short Term Coverage Ratio0.40
Capital Expenditure Coverage Ratio1.64
Dividend Paid and Capex Coverage Ratio1.16
Dividend Payout Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 18.03%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.44, we discern the balance between debt and equity financing. The long-term debt to capitalization, 10.15%, and total debt to capitalization, 30.42%, ratios shed light on its capital structure. An interest coverage of 6.72 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio18.03%
Debt Equity Ratio0.44
Long Term Debt to Capitalization10.15%
Total Debt to Capitalization30.42%
Interest Coverage6.72
Cash Flow to Debt Ratio0.30
Company Equity Multiplier2.42

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 12.87, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.48, reflects the portion of profit attributed to each share. The book value per share, 5.69, represents the net asset value distributed per share, while the tangible book value per share, 4.89, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share12.87
Net Income Per Share0.48
Book Value Per Share5.69
Tangible Book Value Per Share4.89
Shareholders Equity Per Share5.69
Interest Debt Per Share2.17
Capex Per Share-0.46

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 6.78%, indicates top-line expansion, while the gross profit growth, -2.75%, reveals profitability trends. EBIT growth, 5.52%, and operating income growth, 5.52%, offer insights into operational profitability progression. The net income growth, 3.15%, showcases bottom-line expansion, and the EPS growth, -2.04%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth6.78%
Gross Profit Growth-2.75%
EBIT Growth5.52%
Operating Income Growth5.52%
Net Income Growth3.15%
EPS Growth-2.04%
EPS Diluted Growth-2.04%
Weighted Average Shares Growth4.72%
Weighted Average Shares Diluted Growth4.72%
Dividends per Share Growth6.62%
Operating Cash Flow Growth-42.10%
Free Cash Flow Growth-71.35%
10-Year Revenue Growth per Share151.76%
5-Year Revenue Growth per Share33.35%
3-Year Revenue Growth per Share20.99%
10-Year Operating CF Growth per Share426.40%
5-Year Operating CF Growth per Share2.50%
3-Year Operating CF Growth per Share-18.22%
10-Year Net Income Growth per Share424.73%
5-Year Net Income Growth per Share145.71%
3-Year Net Income Growth per Share44.33%
10-Year Shareholders Equity Growth per Share67.93%
5-Year Shareholders Equity Growth per Share37.80%
3-Year Shareholders Equity Growth per Share25.63%
10-Year Dividend per Share Growth per Share13.86%
3-Year Dividend per Share Growth per Share57.06%
Receivables Growth6.36%
Inventory Growth-17.96%
Asset Growth-1.74%
Book Value per Share Growth4.39%
Debt Growth-12.72%
R&D Expense Growth17.65%
SGA Expenses Growth-13.50%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,479,838,097.37, captures the company's total value, considering both debt and equity. Income quality, 1.62, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.01, gauges operational efficiency, while the research and development to revenue, 1.80%, highlights investment in innovation. The ratio of intangibles to total assets, 6.68%, indicates the value of non-physical assets, and capex to operating cash flow, -59.71%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value3,479,838,097.37
Income Quality1.62
Sales General and Administrative to Revenue0.01
Research and Development to Revenue1.80%
Intangibles to Total Assets6.68%
Capex to Operating Cash Flow-59.71%
Capex to Revenue-3.56%
Capex to Depreciation-120.42%
Graham Number7.84
Return on Tangible Assets3.89%
Graham Net Net-4.04
Working Capital-110,724,804
Tangible Asset Value1,625,276,343
Net Current Asset Value-569,583,154
Average Receivables955,335,628.5
Average Payables734,424,247.5
Average Inventory636,363,995
Days Sales Outstanding84
Days Payables Outstanding86
Days of Inventory On Hand66
ROIC6.06%
ROE0.08%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.46, and the price to book ratio, 1.46, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.68, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 29.13, and price to operating cash flows, 11.33, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.46
Price to Book Ratio1.46
Price to Sales Ratio0.68
Price Cash Flow Ratio11.33
Price Earnings to Growth Ratio0.14
Enterprise Value Multiple8.70
Price Fair Value1.46
Price to Operating Cash Flow Ratio11.33
Price to Free Cash Flows Ratio29.13
Price to Tangible Book Ratio1.65
Enterprise Value to Sales0.81
Enterprise Value Over EBITDA9.07
EV to Operating Cash Flow13.66
Earnings Yield5.12%
Free Cash Flow Yield3.30%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 17.711 in 2024.

What is the ticker symbol of Anhui Fengyuan Pharmaceutical Co., Ltd. stock?

The ticker symbol of Anhui Fengyuan Pharmaceutical Co., Ltd. stock is 000153.SZ.

What is company IPO date?

IPO date of Anhui Fengyuan Pharmaceutical Co., Ltd. is 2000-09-20.

What is company current share price?

Current share price is 8.550 CNY.

What is stock market cap today?

The market cap of stock today is 2838822300.000.

What is PEG ratio in 2024?

The current 0.136 is 0.136 in 2024.

What is the number of employees in 2024?

In 2024 the company has 4654.